IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI

IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI

Mostrar otras versiones (1)

Objective: To determine the frequency of immunohistochemical expression of androgen receptor in triple negative breast carcinoma. Study Design: Cross sectional study. Duration and Place of Study: This study included 30 cases confirmed as triple negative breast carcinoma at Armed Forces Institu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Amna Ameer, Farhan Akhtar, Hafeez Ud Din, Rabia Ahmad
Formato: article
Lenguaje:EN
Publicado: Army Medical College Rawalpindi 2021
Materias:
androgen receptor
triple negative breast carcinoma
breast carcinoma
hormone receptors
prognosis
Medicine
R
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/3a03e5e7170d41fd84dadf6292624d28
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Objective: To determine the frequency of immunohistochemical expression of androgen receptor in triple negative breast carcinoma. Study Design: Cross sectional study. Duration and Place of Study: This study included 30 cases confirmed as triple negative breast carcinoma at Armed Forces Institute of Pathology Rawalpindi, from Jan to Jul 2018. Methodology: Anti-androgen receptor antibody was applied and assessed. Positive expression was defined as greater and equal to 10% nuclear immunostaining. SPSS-24 was used for analyzing data. Results: Out of 30 cases of triple negative breast carcinoma (TNBC), all patients were female. Patients’ ages ranged between 21-72 years with a mean age of 46.35 years and a standard deviation of ± 13.4. Androgen receptor expression was positive in 8 cases (27%) of all triple negative breast carcinomas. Out of these androgen receptor (AR) triple negative breast carcinomas; all 8 cases were of histological subtype invasive ductal (mammary) carcinoma, non special type, 7 cases (23%) were of histological grade 3 and 1 was of histological grade 2. Conclusion: Androgen receptor expression is observed in 8 cases (27%) of triple negative breast carcinoma cases. Such patients can be selected as candidates for anti- androgen receptor targeted therapy.

Ejemplares similares